Gail T. McDonald

发表

A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia.

Bingshu E. Chen, Allison M. Booth, S. Mandrekar, 2021, Clinical lymphoma, myeloma & leukemia.

Activated Macrophages Inhibit Human Cytotrophoblast Invasiveness In Vitro1

J. D. Caldwell, S. Renaud, S. Macdonald-Goodfellow, 2005, Biology of reproduction.

Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma: Final results from the MCRN‐003/MYX.1 single arm phase II trial

Bingshu E. Chen, T. Reiman, A. Belch, 2021, American journal of hematology.

INHIBITION OF PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) SIGNALLING LEADS TO RESISTANCE TO CHEMOTHERAPEUTIC AGENTS IN HUMAN CANCER CELLS

Gail T. McDonald, 2008 .

Inhibition of phosphatidylinositol 3-kinase promotes tumor cell resistance to chemotherapeutic agents via a mechanism involving delay in cell cycle progression.

C. Graham, R. Sullivan, Geneviève C. Paré, 2010, Experimental cell research.

Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients With Platinum-Refractory Metastatic Urothelial Cancer: The Canadian Cancer Trials Group BL.12 Randomized Clinical Trial.

M. Stockler, K. Ding, W. Parulekar, 2020, JAMA oncology.

Unusual Carfilzomib Toxicity: Three Cases of Drug-induced Thrombotic Microangiopathy (TMA) after Treatment with High-dose weekly Carfilzomib, Cyclophosphamide, and Dexamethasone (wCCD)

D. Reece, L. Shepherd, M. Lalancette, 2019, Clinical Lymphoma, Myeloma & Leukemia.

Correlation of single arm versus randomised phase 2 oncology trial characteristics with phase 3 outcome.

Bingshu E. Chen, J. Dancey, J. Monzon, 2015, European journal of cancer.

Cctg BL12: Randomized phase II trial comparing nab-paclitaxel (Nab-P) to paclitaxel (P) in patients (pts) with advanced urothelial cancer progressing on or after a platinum containing regimen (NCT02033993).

M. Stockler, K. Ding, W. Parulekar, 2018 .